Colour
C C C C C
Text
T T
Skip To Content

Choroideremia

Gene Therapy
Four Vision Research and Treatment Trends to Watch in 2018   

With the December 2017 announcement that the world’s first ocular gene therapy had received approval by the U.S. Food and Drug Administration (FDA), there’s no doubt that 2017 was a landmark year…

Read More
DNA Strand
First gene therapy for a blinding eye disease receives FDA approval

Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the…

Read More
Dr. Valerie Wallace
Survival of the Fittest: Sustaining Cells Through Transplantation

In many retinal diseases, vision loss occurs when cells that are crucial for vision are damaged or lost. This is the case, for example, in age-related macular degeneration (AMD), retinitis pigmentosa, choroideremia,…

Read More
iPSCs
The Value of iPSCs for Stem Cell Therapy

Stem cell therapy has emerged as one of the most promising approaches in the fight to end blindness, and Dr. Gilbert Bernier’s research has played an enormous role in pushing the field…

Read More
Neon Cells
Clinician-Scientist Emerging Leader Award: Dr. Brian Ballios

Dr. Brian Ballios has restored vision in mice, but he is not stopping there. He is on a mission to develop stem cell therapies for people living with blindness and has a…

Read More
Top 10 Summer Tips Graphic
Top 10 Science-y Summer Tips

So far this year, the pace of vision research has been sizzling! To celebrate the arrival of sizzling weather, we asked Fighting Blindness Canada (FBC) staff to share their favourite FBC science…

Read More

Join the Fight!

Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.

I have read and accepted the privacy policy